Quantcast
Last updated on April 24, 2014 at 10:11 EDT

Latest Tumor necrosis factor-alpha Stories

2010-03-03 07:23:00

GAITHERSBURG, Md., March 3 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system. This preclinical study, "Ad.Egr-TNF and Local Ionizing Radiation Suppress Metastases by Interferon-Beta-Dependent Activation of Antigen-specific CD8+ T Cells," authored by investigators from the University of Chicago and Harvard Medical...

2010-02-22 08:45:00

VIENNA, Va., Feb. 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model. The results were published in the scientific peer-reviewed Journal of International Immunopharmacology (online edition) in an article titled "CEL-2000: A Therapeutic Vaccine for Rheumatoid Arthritis Arrests Disease...

2010-02-10 07:00:00

WALTHAM, Mass., Feb. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel (etanercept)--the leading therapy in the psoriasis drug market in 2008--will account for less than one-fifth of sales in the overall market in 2018. In 2008, Enbrel garnered half of the psoriasis drug market share in the United States,...

2010-01-21 20:35:40

Epidemiological studies indicate that being overweight or obese is associated with increased cancer risk. The most dramatic effect of obesity on cancer risk has been noted for a common form of liver cancer called hepatocellular carcinoma or HCC. Modeling the effect of obesity in mice, researchers at the University of California, San Diego School of Medicine have conclusively demonstrated that obesity is tumor-promoting and have obtained evidence that this effect depends on induction of...

2010-01-21 16:39:22

In a surprising finding, researchers at North Carolina State University have discovered the critical importance of a protein previously believed to be a redundant "on switch" for certain immune-system responses. Scientists previously understood that the protein called TAB2  activates inflammation, an important biological process that stimulates wound-healing and prevents invasion of harmful organisms. But scientists considered TAB2 nonessential to the process due to the redundant...

2010-01-12 07:00:00

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer/Takeda's Enbrel will retain Decision Resources' proprietary clinical gold standard status for the treatment of rheumatoid arthritis through 2018. Although Centocor Ortho Biotech/Merck/Mitsubishi Tanabe/Janssen's Simponi offers delivery advantages over Enbrel in formulation (potentially offered in both...

2010-01-04 07:00:00

WALTHAM, Mass., Jan. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient...

2009-12-16 07:00:00

WALTHAM, Mass., Dec. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to responses from surveyed dermatologists, Centocor Ortho Biotech/Janssen-Cilag's Stelara and Abbott's briakinumab (both interleukin inhibitors) will capture 22 percent of the biologics share in 2012 in the drug market for moderate to severe psoriasis. Among these two agents, Stelara will experience greater...

2009-12-09 07:06:00

WALTHAM, Mass., Dec. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease. Three times as many newly diagnosed second-line patients received a TNF-alpha inhibitor versus one year ago (15.2 percent versus 5.6...

2009-11-30 09:43:00

KING OF PRUSSIA, Pa., Nov. 30 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the completion of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. Results of the safety and tolerability dose escalation study in healthy volunteers confirm the safety of this compound in initial clinical testing. All 30 enrolled subjects completed the study, including those receiving the highest dose...